TargetBeta
DRD3
dopamine receptor D3 · Dopamine receptors
5 programs in company-led studies act on DRD3, from 4 companies: 1 in phase 3, 3 approved with new studies. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Acts as | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|---|
| Olanzapinerule | Eli Lilly | antagonist | phase 4 | 761 running | DRD2, DRD4, HTR2A, HTR2C | ChEMBL |
| rotigotinerule | UCB | agonist | phase 4 | 641 running | DRD2, DRD4 | ChEMBL |
| Pramipexolerule | Boehringer Ingelheim | agonist | phase 4 | 441 running | DRD2, DRD4 | ChEMBL |
| cariprazinerule | AbbVie | – | phase 3 | 414 running | DRD2 | ChEMBL |
| ABBV-932 | AbbVie | agonist | phase 2 | 103 running | DRD2, HTR1A | the company's pipeline |
Conditions their studies are in
- Bipolar Disorder, 3 programs
- Depressive Disorder, Major, 2 programs
- Parkinson Disease, 2 programs
- Restless Legs Syndrome, 2 programs
- Schizophrenia, 2 programs
- Borderline Personality Disorder, 1 program
- Depression, 1 program
- Depressive Disorder, Treatment-Resistant, 1 program
- Fasting, 1 program
- Fibromyalgia, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Nov 2026ABBV-932 · AbbVie · phase 2 · NCT06846320
- Dec 15, 2026cariprazine · AbbVie · phase 3 · NCT03817502
- Dec 2027Olanzapine · Eli Lilly · phase 4 · NCT07565428
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.